Table 2.
Characteristic | Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
HCV-induced HCC | 2.43 (1.43–4.13) | 0.001 | 2.17 (1.21–3.87) | 0.009 |
NASH-induced HCC | 0.23 (0.05–0.94) | 0.04 | 0.74 (0.16–3.43) | 0.70 |
BCLC stage | ||||
|
||||
|
2.74 (1.40–5.34) | 0.003 | 2.82 (1.37–5.81) | 0.005 |
|
2.93 (1.42–6.06) | 0.004 | 2.72 (1.22–6.05) | 0.01 |
Previous treatment | 2.33 (1.41–3.85) | 0.001 | 1.66 (0.96–2.86) | 0.07 |
Markers of portal hypertension a | 2.07 (1.24–3.45) | 0.005 | 1.37 (0.79–2.38) | 0.26 |
High visceral adipose Radiodensity (VAT HU≥ −85 HU) |
2.56 (1.54–4.26) | 0.002 | 2.01 (1.14–3.54) | 0.02 |
BCLC, Barcelona-Clinic Liver Cancer; CI, confidence interval, HCV, hepatitis C; HR, hazard Ratio; NASH, non-alcoholic steatohepatitis. a Markers of portal hypertension includes splenomegaly, esophageal varices or thrombocytopenia (platelet count <100,000/mm3). HRs and P values were estimated using Cox proportional hazard model.